Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

Start Date01 Mar 2025

Sponsor / Collaborator

Wake Forest School of Medicine

NCT06693726

/ Not yet recruitingPhase 4IIT

ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study

This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration (within 3 hours of norepinephrine initiation) of angiotensin II for treatment of septic shock in the ED

Start Date31 Jan 2025

Sponsor / Collaborator

University of Iowa

NCT06615102

/ Not yet recruitingPhase 3IIT

A Prospective Angiotensin II Versus Noradrenaline Trial for Hypotension Management to Reduce Cardiac-surgery Associated Acute Kidney Injury (PAN-AKI)

The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.

Start Date01 Jan 2025

Sponsor / Collaborator

Westfälische Wilhelms-Universität Münster

[+1]

100 Clinical Results associated with Angiotensin II Acetate

100 Translational Medicine associated with Angiotensin II Acetate

100 Patents (Medical) associated with Angiotensin II Acetate

10,877

Literatures (Medical) associated with Angiotensin II Acetate

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Sirtuin 1 mediates the pro-survival effects of vitamin D in angiotensin II-induced hypertrophy of H9c2 cardiomyoblasts

Article

Author: Hekmatimoghaddam, Seyedhossein ; Sarebanhassanabadi, Mohammadtaghi ; Maroofi, Abdulbaset ; Astani, Akram ; Safari, Fatemeh

BACKGROUND:

The role of 1,25-dihydroxyvitamin-D3 (VitD) and sirtuin-1 (SIRT1) in mitigating pathological cardiac remodeling is well recognized. However, the potential for SIRT1 to mediate the inhibitory effects of VitD on angiotensin II (Ang II) -induced hypertrophy in H9c2 cardiomyoblasts remains unclear.

METHODS:

H9c2 cardiomyoblasts were exposed to Ang II or a combination of VitD and Ang II, both in the absence and presence of SIRT1-specific siRNA. In each cell group, cell viability, hypertrophy, and redox state were evaluated using relevant techniques.

RESULTS:

In H9c2 cells transfected with SIRT1 siRNA, VitD failed to significantly counteract the Ang II-induced perturbations, which included a reduction in cell viability, decreased CAT and SOD activity/mRNA levels, diminished MnSOD mRNA levels, and increased MDA content. Conversely, VitD significantly inhibited Ang II-induced hypertrophy in H9c2 cells by reducing cell size and lowering ANP and BNP mRNA levels, regardless of SIRT1 status. Notably, neither Ang II nor VitD altered the expression of SIRT1 mRNA or protein in H9c2 cells.

CONCLUSION:

SIRT1 serves as an important regulator of pro-survival, but not anti-hypertrophic functions of VitD in hypertrophied cardiomyoblasts. Indeed, the absence of SIRT1 jeopardizes the capabilities of VitD to confer its pro-survival activity in H9c2 cells. Therefore, SIRT1-centered activating compounds may augment the protective effects of VitD, providing a promising therapeutic strategy to reduce the risk of cardiac hypertrophy and heart failure.

01 Feb 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Clinically approved representative small-molecule drugs for cardiopathy therapy

Review

Author: Li, Bin ; Ma, Shaowei ; Jiang, Min ; Wang, Xiao

The application of therapeutic agents for cardiopathy has brought about significant advancements in the treatment of cardiovascular diseases. The intervention of small-molecule drugs has led to substantial reductions in morbidity and mortality rates, along with decreased utilization of healthcare resources. However, current treatment modalities do not exhibit uniform efficacy across all patients, and the emergence of drug resistance poses a significant challenge to further therapeutic efforts. Additionally, chronic administration of these drugs can result in toxicities, adding complexity to long-term management. This review focuses on the application of clinically approved small-molecule drugs for the treatment of cardiopathy, covering major classes such as angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers, β-blockers, and sodium-glucose co-transporter 2 inhibitors. The review provides an in-depth analysis of their synthetic routes, mechanisms of action, and roles in cardiopathy treatment. It also offers perspectives on future directions in the development of next-generation cardioprotective agents, aiming to optimize therapeutic strategies for cardiovascular disease management.

03 Jan 2025·CIRCULATION RESEARCH

A Vaccine Against Fibroblast Activation Protein Improves Murine Cardiac Fibrosis by Preventing the Accumulation of Myofibroblasts

Article

Author: Sun, Jiao ; Nakagami, Hironori ; Hayashi, Hiroki ; Katsuya, Tomohiro ; Yoshida, Shota ; Shimamura, Munehisa ; Baba, Satoshi ; Kimura, Mitsukuni ; Rakugi, Hiromi ; Morishita, Ryuichi ; Toyoura, Masayoshi ; Nakamaru, Ryo ; Hino, Rissei ; Kawahara, Takuro ; Katsuki, Shunsuke ; Tenma, Akiko ; Matoba, Tetsuya

BACKGROUND::

Myofibroblasts are primary cells involved in chronic response-induced cardiac fibrosis. Fibroblast activation protein (FAP) is a relatively specific marker of activated myofibroblasts and a potential target molecule. This study aimed to clarify whether a vaccine targeting FAP could eliminate myofibroblasts in chronic cardiac stress model mice and reduce cardiac fibrosis.

METHODS::

We coadministered a FAP peptide vaccine with a cytosine-phosphate-guanine (CpG) K3 oligonucleotide adjuvant to male C57/BL6J mice and confirmed an elevation in the anti-FAP antibody titer. After continuous angiotensin II and phenylephrine administration for 28 days, we evaluated the degree of cardiac fibrosis and the number of myofibroblasts in cardiac tissues.

RESULTS::

We found that cardiac fibrosis was significantly decreased in the FAP-vaccinated mice compared with the angiotensin II and phenylephrine control mice (3.45±1.11% versus 8.62±4.79%; P =4.59×10 −3 ) and that the accumulation of FAP-positive cells was also significantly decreased, as indicated by FAP immunohistochemical staining (4077±1746 versus 7327±1741 cells/mm 2 ; FAP vaccine versus angiotensin II and phenylephrine control; P =6.67×10 −3 ). No systemic or organ-specific inflammation due to antibody-dependent cell cytotoxicity induced by the FAP vaccine was observed. Although the transient activation of myofibroblasts has an important role in maintaining the structural robustness in the process of tissue repair, the FAP vaccine showed no adverse effects in myocardial infarction and skin injury models.

CONCLUSIONS::

Our study demonstrates the FAP vaccine can be a therapeutic tool for cardiac fibrosis.

News (Medical) associated with Angiotensin II Acetate

17 Dec 2024

·www.globenewswire.com

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea’s hospital anti-MRSA antibiotic Zevtera® (ceftobiprole) in the United States (US). Innoviva Specialty Therapeutics is a US-based biopharmaceutical company with an established hospital sales force and a core competence in commercializing anti-infective medicines. David Veitch, Chief Executive Officer of Basilea, stated: “We are very pleased with our collaboration with Innoviva Specialty Therapeutics for the commercialization of Zevtera in the US. The company is a highly committed, focused and capable partner that shares our vision and ambitions for Zevtera in the US. They also have recent experience of launching a hospital antibiotic in the US. We are looking forward to working with Innoviva Specialty Therapeutics towards a successful launch and bringing Zevtera to patients in need in the US.” “With this agreement, Zevtera will become an important asset in our company’s portfolio, allowing us to advance our strategy of providing differentiated therapies in infectious disease and critical care,” said Pavel Raifeld, Chief Executive Officer, Innoviva, Inc. “There is a significant medical need for treatments targeting complicated Staphylococcus aureus infections, particularly Staphylococcus aureus bacteremia. We are therefore excited to bring this important new medicine to patients who are suffering from these severe infections.” Under the terms of the agreement, Basilea will receive a USD 4 million upfront payment and tiered royalties on net sales in the high-teens to mid-twenties percentage range. Basilea will be eligible to receive sales milestones of up to USD 223 million. In addition, Innoviva Specialty Therapeutics will purchase its demand of Zevtera drug product from Basilea. Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria, such as Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria.1 In several countries in Europe and beyond, the brand is currently approved and marketed as Zevtera® and Mabelio® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP). Basilea has entered into license and distribution agreements covering more than 80 countries. In the United States, Zevtera is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).2 Basilea’s ceftobiprole phase 3 program is funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work. Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. References Summary of Product Characteristics (SmPC) Zevtera: https://www.medicines.org.uk/emc/product/9164/smpc [Accessed: December 15, 2024] Full US prescribing information: https://www.basilea.com/ZEVTERA_US_prescribing_information_46b9y4wk The content above comes from the network. if any infringement, please contact us to modify.

License out/inDrug Approval

16 Dec 2024

·www.businesswire.com

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

BURLINGAME, Calif.--( BUSINESS WIRE )--Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), for the commercialization of Zevtera ® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the United States. "The licensing of Zevtera expands IST’s diverse yet complementary portfolio of differentiated treatments that address substantial unmet medical needs,” said Pavel Raifeld, Chief Executive Officer, Innoviva, Inc. “We are excited to leverage our operating platform to deliver this important drug to patients. The transaction reinforces the significant opportunity for growth we see in our therapeutics business, building on the momentum and success we have had with our existing marketed products.” In April 2024, the U.S. Food and Drug Administration (FDA) approved Zevtera for three specific treatment indications, and it is the only FDA-approved methicillin-resistant Staphylococcus aureus (MRSA) cephalosporin antibiotic for treating adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB) and endocarditis. Zevtera is indicated for the treatment of adult patients with SAB, including right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections (ABSSSI) and for adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP). 1 "Zevtera strengthens our role as a provider of essential therapeutics for infectious diseases and critical care within our primary customer base," stated David Altarac, Chief Medical Officer of Innoviva Specialty Therapeutics, Inc. “Drug-resistant pathogens, like MRSA, pose significant challenges for patients in hospitals and other healthcare facilities with a high mortality rate and huge cost burden. Zevtera will enable physicians to treat this important pathogen more effectively, as it is the only approved cephalosporin specifically for MRSA bloodstream infections.” Under the terms of the agreement, Innoviva, Inc., will be granted exclusive marketing rights to Zevtera in the U.S. Basilea will receive a $4 million upfront payment in addition to tiered royalties and milestones on net sales in the U.S. Innoviva Specialty Therapeutics anticipates commercializing Zevtera in mid-year 2025. Reference Full US prescribing information: https://www.basilea.com/ZEVTERA_US_prescribing_information_46b9y4wk About Zevtera ® (ceftobiprole medocaril sodium for injection) Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced generation cephalosporin antibiotic for intravenous administration, with rapid bactericidal activity against a wide range of Gram-positive bacteria, such as Staphylococcus aureus , including methicillin-resistant strains (MRSA), and Gram-negative bacteria. 1 Outside the U.S., the brand is currently approved and marketed in several countries in Europe and beyond as Zevtera ® and Mabelio ® for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP). Basilea has entered into license and distribution agreements covering more than 80 countries. Important US safety information for ZEVTERA (ceftobiprole medocaril sodium for injection) Contraindications ZEVTERA is contraindicated in patients with a known history of severe hypersensitivity to ZEVTERA, or to other members of the cephalosporin class. Warnings and precautions Increased Mortality with Unapproved use in Ventilator-Associated Bacterial Pneumonia (VABP) Patients: The safety and effectiveness of ZEVTERA for the treatment of VABP has not been established and the use of ZEVTERA for VABP is not approved. Hypersensitivity Reactions: Discontinue ZEVTERA if a hypersensitivity reaction occurs, and institute appropriate treatment. Seizures and other adverse central nervous system (CNS) reactions have been associated with the use of ZEVTERA. If seizures or other CNS adverse reactions occur, evaluate patients to determine whether ZEVTERA should be discontinued. Clostridioides difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including ZEVTERA. Evaluate if diarrhea occurs. Adverse reactions SAB (adult patients): The most common adverse reactions occurring in ≥ 4% of adult patients were anemia, nausea, hypokalemia, vomiting, hepatic enzyme and bilirubin increased, diarrhea, blood creatinine increased, hypertension, leukopenia and pyrexia. ABSSSI (adult patients): The most common adverse reactions occurring in ≥ 2% of adult patients were nausea, diarrhea, headache, injection site reaction, hepatic enzyme increased, rash, vomiting, and dysgeusia. CABP (adult and pediatric patients 3 months to less than 18 years of age): Adult Patients: The most common adverse reactions occurring in ≥ 2% of adult patients were nausea, hepatic enzyme increased, vomiting, diarrhea, headache, rash, insomnia, abdominal pain, phlebitis, hypertension and dizziness. Pediatric Patients: The most common adverse reactions occurring in ≥ 2% of pediatric patients were vomiting, headache, hepatic enzyme increased, diarrhea, infusion site reaction, phlebitis and pyrexia. For full US prescribing information, please visit here: www.basilea.com/ZEVTERA_US_prescribing_information_46b9y4wk About Staphylococcus aureus bacteremia (SAB) Staphylococcus aureus bacteremia (SAB) is a serious bloodstream infection associated with significant morbidity and mortality. Complications include concomitant infections such as bone, joint or heart valve infections, persistent bacteremia or bacteremia in patients on dialysis. With a 30-day all-cause mortality of around 20% there is a high medical need for improved therapies for SAB. About acute bacterial skin and skin structure infections (ABSSSI) Acute bacterial skin and skin structure infections (ABSSSI) are common infections in the healthcare setting. Staphylococcus aureus is the most common pathogen associated with these infections, which can be difficult to treat if methicillin-resistant Staphylococcus aureus (MRSA) is involved. About community-acquired bacterial pneumonia (CABP) Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity and mortality worldwide. It is the leading cause of infectious disease-related death in the US. For full prescribing information go to https://www.basilea.com/ZEVTERA_US_prescribing_information_46b9y4wk About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® . Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA ® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA ® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. ANORO ® , RELVAR ® and BREO ® are trademarks of the GSK group of companies.

License out/inDrug Approval

26 Nov 2024

·www.businesswire.com

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

BURLINGAME, Calif.--( BUSINESS WIRE )--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Citi 2024 Global Healthcare Conference in Miami, FL on Thursday, December 5, 2024 at 8:45 a.m. Eastern Time. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events . The webcast will be available for replay for 90 days following the event. About Innoviva Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ® . Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA ® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA ® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. ANORO ® , RELVAR ® and BREO ® are trademarks of the GSK group of companies.

Drug ApprovalAcquisition

100 Deals associated with Angiotensin II Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Angiotensin II Acetate	C01CX09	DB11842

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Distributive shock	EU	PAION AG	23 Aug 2019
Distributive shock	IS	PAION AG	23 Aug 2019
Distributive shock	LI	PAION AG	23 Aug 2019
Distributive shock	NO	PAION AG	23 Aug 2019
Hypotension	EU	PAION AG	23 Aug 2019
Hypotension	IS	PAION AG	23 Aug 2019
Hypotension	LI	PAION AG	23 Aug 2019
Hypotension	NO	PAION AG	23 Aug 2019
Shock, Septic	EU	PAION AG	23 Aug 2019
Shock, Septic	IS	PAION AG	23 Aug 2019
Shock, Septic	LI	PAION AG	23 Aug 2019
Shock, Septic	NO	PAION AG	23 Aug 2019
Shock	US	La Jolla Pharma LLC	21 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver transplant rejection	Phase 3	US	La Jolla Pharmaceutical Co.	28 Jun 2022
Vasoplegia	Phase 3	US	La Jolla Pharmaceutical Co.	28 Jun 2022
Sepsis	Phase 3	US	La Jolla Pharmaceutical Co.	01 Mar 2015
Sepsis	Phase 3	AU	La Jolla Pharmaceutical Co.	01 Mar 2015
Sepsis	Phase 3	BE	La Jolla Pharmaceutical Co.	01 Mar 2015
Sepsis	Phase 3	CA	La Jolla Pharmaceutical Co.	01 Mar 2015
Sepsis	Phase 3	FI	La Jolla Pharmaceutical Co.	01 Mar 2015
Sepsis	Phase 3	FR	La Jolla Pharmaceutical Co.	01 Mar 2015
Sepsis	Phase 3	DE	La Jolla Pharmaceutical Co.	01 Mar 2015
Sepsis	Phase 3	NZ	La Jolla Pharmaceutical Co.	01 Mar 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04558359 (CTgov)	Phase 4	Acute Kidney Injury \| Shock, Septic	30	Standard of Care (Standard of Care Cohort)	dkxjzoshrx(atwljsaoou) = aszrdnedra vgtssysaos (mbhqwahzyr, hnhvijbghp - utagbtljte) View more	-	04 Sep 2024
				Angiotensin II (Angiotensin II Cohort)	dkxjzoshrx(atwljsaoou) = wehefgniyd vgtssysaos (mbhqwahzyr, vqxsvwzlwa - iuazowdesl) View more
ATS2024	Not Applicable	Respiratory Distress Syndrome, Adult \| Distributive shock	-	Angiotensin-II	zczbcubbxv(zwlmeypugo) = tightpigyi dqrhtkvguk (tlrbdypnak, 160) View more	-	19 May 2024
				Placebo	zczbcubbxv(zwlmeypugo) = ousrpcixhn dqrhtkvguk (tlrbdypnak, 74) View more
NCT01393782 (ATHOS, CTgov)	Phase 1	Shock, Septic \| Shock \| Hypotension	20	Angiotensin II (Angiotensin)	anbickqxtb(epjyfsfprp) = qvwxxlsjnk oycvlrpcwn (xrznkbyjec, ksuxdugwlh - louchvwhkl) View more	-	12 Apr 2024
				Angiotensin II (Control)	anbickqxtb(epjyfsfprp) = ozzykysulj oycvlrpcwn (xrznkbyjec, utuuttmitg - iipcybzgxc) View more
ESC2024	Not Applicable	Shock	-	Angiotensin II	qikfduepcp(lcitnpnzst) = lcxdcoqutp bxnvqcfmvy (vqyqgkwtiv, 41 - 56) View more	-	08 Mar 2024
NCT02338843 (ATHOS-3, Pubmed \| Ann Intensive Care)	Phase 3	Respiratory Distress Syndrome, Acute \| Shock	81	Angiotensin-II	rlnwilptns(ztqmkkgshk) = lorkylgkag kbtzvaxtgc (oudetsfcif ) View more	Positive	16 Dec 2023
				Placebo	rlnwilptns(ztqmkkgshk) = bruygnevaq kbtzvaxtgc (oudetsfcif ) View more
ATS2023	Not Applicable	Drug Overdose	-	Angiotensin II	fcpegeddfz(ynxzumhdyg) = zzciyuagft xbfnwcwtbj (yitzjfrbun )	-	21 May 2023
NCT02338843 (ATHOS-3, Pubmed)	Phase 3	Shock	321	Angiotensin II	mxxzklozam(xmkbzuprik): HR = 0.509 (95% CI, 0.274 - 0.945), P-Value = 0.03 View more	-	05 May 2023
				Placebo
NCT04529005 (CTgov)	Phase 4	Transplant complication \| Shock \| Hypotension	20	Angiotensin II	imtthghguv(rglcobkmze) = zftdhtuwyh krefuvfrdf (otqglexwba, tcvrttinml - enyhiibyvf) View more	-	21 Dec 2022
ASN2022	Not Applicable	GSTM1 deficiency	-	Angiotensin II (Gstm1 knockout (KO))	wbhcviqmsf(dvtidhygsw) = nevxivhfld umbfxqtdvv (fzvpullcna )	-	05 Nov 2022
				Angiotensin II (Wild-type (WT))	wbhcviqmsf(dvtidhygsw) = qlabxqklsl umbfxqtdvv (fzvpullcna )
ATS2022	Not Applicable	Shock, Septic	-	Angiotensin II	ouwgkxuihn(gtrhwsfaby) = iymxcuwbbl hkegmonlkw (daxbinvzku ) View more	Positive	15 May 2022
				No Angiotensin II	ouwgkxuihn(gtrhwsfaby) = nmuwofrgae hkegmonlkw (daxbinvzku ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis